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ABSTRACT 
 
Background: Cancer is a leading health problem throughout the world. For decades, natural plant 
products have been playing promising roles as anticancer agents.  
Objective: The present study aims to investigate the chemotherapeutic potential of methyl 
angolensate (MA), purified from Soymida febrifuga in mice bearing carcinoma and examines the 
molecular basis for its anticancer actions.  
Study Design: The inhibitory effects of MA treatment on the survival of mice bearing Carcinoma 
and adverse side effects of MA treatment in mice were analyzed.  
Methods: Tumor volume, life span, histopathology, immunohistochemical (IHC) analysis, estimation 
of liver enzyme, alkaline phosphatase and metabolites, creatinine and urea.  
Results: Oral administration of MA in mice with Ehrlich Ascites Carcinoma showed significant 
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inhibition of tumor growth compared to untreated mice. We observed a significant increase in the life 
span (~4-fold) of tumor bearing animals following treatment with MA. MA affected tumor cell 
proliferation by activating intrinsic pathway of apoptosis without imparting any side effect on normal 
cells. MA treatment in mice showed no major side effects.  
Conclusion: MA treatment showed significant inhibition of tumor growth by inducing apoptosis as 
well increased life span of mice, with no adverse side effects to normal cells. Altogether, the present 
in vivo study provides new insights of MA serving as a cancer chemotherapeutic agent.  
 
 
Keywords: Methyl angolensate; apoptosis; tumor; carcinoma; chemotherapy; natural products. 
 
ABBREVIATIONS 
 
MA-Methyl Angolensate, EAC- Ehrlich Ascites Carcinoma, IHC- Immunohistochemistry, b.wt.- Body 
weight, ALP- Alkaline phosphatase, p53BP1-p53 binding protein. 
 
1. INTRODUCTION 
 
Cancer continues to be a leading health problem 
throughout the world, despite momentous 
research efforts towards development of 
therapeutics. Significant advancement in 
preventive and therapeutic approaches is crucial 
for reducing cancer associated mortality. For 
decades, plant products have been playing 
promising roles as anticancer agents. One such 
group of phytochemicals, the triterpenoids have 
demonstrated chemopreventive and therapeutic 
effects [1-5]. In this regard, the recently reported 
natural tetranortriterpenoid, methyl angolensate 
(MA) (Fig. 1A), is of immense interest. MA is 
known to be chemopreventive, antimalarial [6], 
anti-inflammatory [7], antiallergic [8], antifungal 
[9] antiulcer [10], spasmolytic [11], insect 
antifeedant [12] and antibacterial in action.  
 
Previously, utilizing cell based assays, we 
reported that MA exhibited time- and dose-
dependent cytotoxicity to human T-cell leukemia, 
chronic myelogenous leukemia, Burkitt’s 
lymphoma and breast cancer cells [13-16]. The 
observed cytotoxicity in normal lymphoblastoid 
cell lines was minimal suggesting that its mode of 
action was specific to cancer cells. Besides, 
treatment of MA led to activation of NHEJ 
machinery in Burkitt’s lymphoma cells suggesting 
activation of DNA repair pathway [16]. Strikingly, 
MA treatment also resulted in phosphorylation of 
signaling molecules such as ERK1/2, JNK and 
MEK1/2 in cancer cells implying their role in 
apoptotic signal transduction. Although the action 
of MA against various types of cancer cell lines 
suggested its potential as an anticancer agent, 
its effects in primary tumor cells or tumors in vivo 
remained unexplored. 
 
Here, we show that MA impedes tumor 
progression in mice similar to a positive control, 
SCR7, a small molecule inhibitor that possess 
anticancer properties. Histopathological and 
immunohistochemistry studies demonstrate that 
MA treatment affects only tumor cell proliferation, 
sparing normal cells. Further, our data indicates 
that MA activates intrinsic pathway of apoptosis. 
Finally, we show that treatment with MA results 
in significant increase in life span of mice with no 
adverse effects. 
 
2. MATERIALS AND METHODS 
 
2.1 Methyl Angolensate (MA) 
 
MA used in the present study was dissolved in 
0.5% methyl cellulose and used for animal 
experiments. 
 
2.2 Ethical Statement 
 
Mice were maintained as per the principles and 
guidelines of the ethical committee for animal 
care at Indian Institute of Science, which was in 
accordance with Indian National Law on animal 
care and use. The experimental design of the 
present study was approved by Institutional 
Animal Ethics Committee (Ref. 
CAF/Ethics/125/2007/560), Indian Institute of 
Science, Bangalore, India.  
 
2.3 Evaluation of Anticancer Effect of MA 
on Solid Tumor Progression 
 
Swiss albino mice, 8-10 weeks old, weighing 18-
24 g were used for the present study. For the 
pilot experiments to determine the optimum dose 
of MA required for tumor regression, 6 Swiss 
albino mice were injected with EAC cells (1×10
6
 
cells/animal) into left thigh for the development of 
solid tumor. The mice were divided randomly into 
three groups of two animals each, on the 15
th
 
 
 
 
 
Chiruvella et al.; BJMMR, 12(11): 1-10, 2016; Article no.BJMMR.21952 
 
 
 
3 
 
day of tumor induction. Group I animals served 
as tumor control and received equivalent volume 
of 0.5% methylcellulose (vehicle control). Group 
II and III were orally administered 10 and 30 
mg/kg b. wt. MA (6 doses), respectively, every 
alternate day. Increase in tumor volume was 
measured using vernier calipers every alternate 
day.  
 
MA used for further experiments was 30 mg/kg b. 
wt. 30 mice were used per batch, which was 
divided randomly into three groups of 10 animals 
each. Group I animals served as untreated 
control and received no treatment. Group II and 
III were injected with EAC cells (1×106 
cells/animal) into left thigh for the development of 
solid tumor. Group II animals served as tumor 
control and received equivalent volume of 0.5% 
methyl cellulose. Group III animals received oral 
administration of MA (30 mg/kg b.wt., dissolved 
in 0.5% methyl cellulose, 9 doses) at an interval 
of two days using intra gastric gavage from 12th 
day of tumor development.  
 
Tumor volume was measured every alternate 
day during the entire life span and was 
calculated using the formula V = 0.5 x a x b2, 
where ‘a’ and ‘b’ indicates the major and minor 
diameters, respectively [17-20]. At the end of 25th 
and 45
th
 day, one animal from each group was 
sacrificed and organs of interest were collected 
from untreated control, tumor control and MA 
treated animals and further processed for 
histological evaluation.  
 
2.4 Determination of Effect of MA on 
Survival of Tumor Bearing Mice 
 
The percentage increase in life span was 
calculated by using the formula ((T − C)/C) × 
100, where ‘T’ indicates the number of days the 
treated animals survived and ‘C’ indicates the 
number of days the control tumor animals 
survived [17-21]. Animals were maintained till 
their natural death. However, few animals which 
were high in tumor burden were sacrificed before 
their natural death. 
 
2.5 Determination of the Side Effects of 
Administration of MA in Mice 
 
Serum was collected from blood of control (n=4) 
and MA administered (n=4; 30 mg/kg b. wt., 9 
doses, every alternate day). Body weights of 
mice from both the groups were recorded 20 
days after treatment. Liver and kidney function 
tests were performed as described, to check the 
toxicity induced by MA treatment [17,22]. Levels 
of alkaline phosphatase activity served as an 
index of liver functionality. Kidney function was 
determined by checking urea and creatinine 
levels in the serum. Blood collected from mice in 
both the groups was used for obtaining mean 
values of total red blood (RBC) and white blood 
cells (WBC) counts using a haemocytometer. 
Values are presented as mean ± SEM for the 
control and MA administered mice. 
 
2.6 Histopathological Evaluation Immuno-
histochemical (IHC) Analysis 
 
The tissues and organs of interest (tumor and 
liver) collected from the animals were processed 
as per standard protocol and embedded in 
paraffin. Microtome sectioning was done at 3–
5 μm in a rotary microtome (Leica Biosystems, 
Germany) and stained with hematoxylin and 
eosin [17,18,22,23]. Each section was evaluated 
using light microscopy and images were 
captured (Carl Zeiss, Germany). 
 
2.7 Immunohistochemical (IHC) Analysis 
  
Immunostaining of tumor and MA treated tissue 
was performed on formalin fixed, paraffin 
embedded tissues and sectioned at 3-5 μm 
thickness as described [18,22]. Rabbit polyclonal 
antibodies Ki67, BID and p53BP1 (Santa Cruz 
Biotechnology) and biotinylated anti-rabbit IgG 
were used. Multiple images from control and 
treated groups were quantified using ImageJ. 
 
2.8 Statistical Analysis 
 
Values were expressed as mean ± SEM for 
control and experimental samples and statistical 
analysis was performed by one-way ANOVA 
followed by Turkey-Kramer Multiple Comparison 
test using GraphPad prism 5.1. Values were 
considered statistically significant, if the p-value 
was less than 0.05. 
 
3. RESULTS 
 
3.1 MA Prevents Tumor Progression in 
Mice 
 
In order to evaluate the potential of MA as an 
anticancer agent, mice harboring EAC induced 
tumor were utilized. EAC is a murine breast 
adenocarcinoma extensively used for analyzing 
effects of small molecule inhibitors on tumor 
progression. A pilot study was performed using 
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EAC induced Swiss albino mice for determining 
the dose of MA needed for tumor regression (Fig. 
1B). The tumor induced mice were treated with 
two doses of MA (10 or 30 mg/kg b.wt) or an 
equivalent volume of vehicle control. 
Interestingly, we found that, while tumor volume 
increased exponentially in the untreated group, in 
both the treated groups the tumor progression 
was reduced (Fig. 1B). The tumor regression 
was pronounced in the group treated with 30 
mg/kg b.wt. MA, while it was minimal when the 
lower dose was used (Fig. 1B). Importantly, the 
mice showed no observable difference in 
appearance or body weight (data not shown) 
implying that MA did not adversely affect its 
health. 
 
Based on the above results, therapeutic potential 
of MA was extensively assayed in three 
independent batches of experiments (in each 
experiment, 10 each untreated normal control, 
untreated tumor control and tumor mice treated 
with MA) at a dose of 30 mg/kg b.wt. (Fig. 1C). 
Following the development of tumor, 12th day 
post EAC injection, the mice were orally fed with 
MA on every alternate day (9 doses). Fig. 1C 
showed remarkable reduction in tumor size upon 
treatment with MA as compared to untreated 
animals. Fig. 1D shows average tumor volume in 
untreated animals was 14.78, 13.84, 18.94, 
23.89 and 38.76 cm3 on 10th, 20th, 30th, 40th and 
50th day respectively, whereas it was only 6.56, 
5.22, 6.16, 1.57 and 0.0 cm
3
 respectively, upon 
MA treatment (Fig. 1C). We found that 83% 
(25/30) of the mice with tumor were dead by 50
th
 
day of tumor development when left untreated. 
Interestingly, 70% (21/30) of the mice survived 
following treatment with MA up to at least 300 
days (Fig. 1D).  
 
SCR7 is an inhibitor of nonhomologous DNA end 
joining (NHEJ), and shown to possess antitumor 
activity in mice [18,24-26]. Therefore, we have 
used SCR7 as a positive control for tumor 
regression. Upon treatment with SCR7 in mice 
bearing EAC induced tumors we found significant 
tumor regression in tumor volume, while the 
growth was exponential in the untreated group 
(Fig. 1E). 
 
3.2 MA Treatment Significantly Increased 
the Survival of Tumor Bearing Mice 
 
We observed lifespan was significantly increased 
in MA treated tumor mice compared to that of 
untreated tumor animals (Fig. 1D). While control 
animals survived maximum of only 68 days after 
tumor development, 50% of the MA treated mice 
survived upto >200 days and 25% of the mice 
survived upto 300 days indicating significant 
increase in life span (Fig. 1D). Therefore, our 
results suggest that MA treatment inhibited tumor 
progression and improved the survival of mice, 
significantly.  
 
Next, we performed histopathological 
examination of tumor and liver tissues of MA 
treated mice on 25th and 45th days, for analyzing 
cellular level changes and toxicity caused by MA. 
Hematoxylin-eosin stained sections of 25th and 
45
th 
day untreated tumor showed cellular 
damage, angiogenesis and tumor cell 
proliferation (Fig. 2A (b, e), B (b, e)) as compared 
to normal untreated mice thigh tissue (Fig. 2A (a, 
d), B (a,d)). However, tumor tissues showed very 
high tumor cell proliferation and complete 
destruction of cellular architecture. Interestingly, 
tumor tissue from MA treated mice showed               
only mild cell architecture damage, while 
proliferation of tumour cells was reduced (Fig. 2A 
(c, f), B (c, f)). When similar tissue sections were 
examined after 45 days of tumor development, 
the effect was very prominent following MA 
treatment and it could be seen that the tissues 
were restored to normal cellular morphology      
(Fig. 2B (c, f)). 
 
Histopathological sections of liver from normal 
mouse showed proper arrangement of 
hepatocytes with no infiltration (Fig. 2C (a, d), D 
(a, d)), while liver from tumor bearing mouse 
after completion of 25 days of treatment showed 
infiltration of hepatocytes, cellular damage and 
dilation of central veins (Fig. 2C (b, e), D (b, e)). 
In contrast, liver from MA treated mouse showed 
dilated sinusoids with minimum infiltration of 
hepatocytes and nearly normal rearrangement of 
hepatic cell chords (Fig. 2C (c, f)). However, the 
effect was more pronounced when tissues were 
analysed following 45 days of MA treatment           
(Fig. 2D (c, f)). Thus, our results showed that MA 
treatment significantly reduced the tumor burden. 
 
3.3 MA Abrogates Tumor Progression 
with no Side Effects 
 
Next we evaluated the side effects of MA 
treatment for serum levels were analysed for liver 
enzyme such as Alkaline phosphatase (ALP), 
and metabolites like creatinine and urea. Results 
showed no significant difference in the serum 
levels of ALP, creatinine and urea between 
untreated control and MA treated mice groups 
suggesting that there were no adverse effects of 
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MA on liver and kidney functions (Fig. 3A). 
Further, we did not observe any effect of MA on 
the total RBC and WBC counts suggesting that it 
did not affect hematopoiesis. Analysis for toxicity 
on 0th day after oral administration of MA showed 
that there was no significant change in the body 
weight among the control and treated groups 
(Fig. 3B). Thus, our data indicates that MA 
treatment does not result in any apparent side 
effects in normal mice. 
 
3.4 MA Induces Cell Death through 
Activating Apoptosis 
 
Previously studies on cancer cell lines suggested 
that MA induced apoptosis by activating
  
 
 
Fig. 1A. Structure of methyl angolensate. B. Pilot experiment to evaluate the effect of MA on 
mice bearing tumor. Solid tumor was induced intramuscularly in Swiss albino mice by 
injecting EAC cells (1x10
6 
cells/animal). From 15
th
 day of EAC injection, MA (10 or 30 mg/kg b. 
wt.) was orally administered (6 doses) every alternate day. The tumor volume was measured 
and plotted against the day of measurement. Two mice per group were used for the 
preliminary study. C-E. Effect of MA on tumor progression and life span of EAC induced mice. 
C.  Solid tumor was induced as described above. Tumor volume in control and MA treated 
tumor-bearing mice at different time intervals. From 12
th
 day of EAC injection, MA (30 mg/kg b. 
wt.) was orally administered (9 doses) at an interval of two days and the tumor volume was 
calculated. D. Evaluation of effect of MA treatment on life span in tumor bearing mice. Kaplan–
Meier survival curves for control and MA treated mice. ‘‘EAC alone’’ refers to control mice 
injected with EAC cells while ‘‘EAC+MA’’ indicates the mice-bearing tumor treated with MA. 
Error bars indicate SD from independent experiment. Data shown is obtained from three 
independent batches of experiments containing 10 animals per group. E. Effect of SCR7, a 
positive control on tumor progression and life span of EAC induced mice. EAC induced mice 
were treated with vehicle control or SCR7 (10 mg/kg b. wt.) intraperitonially (6 doses) every 
alternate day. The tumor volume was measured and plotted against as above. Each group 
consisted of six mice and the error bar is plotted 
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Fig. 2. Histopathology of tumor and liver following MA treatment 
Histopathological sectioning of tumor and liver tissues of mice following MA treatment after 25 and 45 days of 
treatment with MA. A-B. Microscopic images of histological sections of thigh tissues on 25
th
and 45
th
 days, 
respectively. C-D. Histological sections of liver tissues on 25
th
and 45
th
 days, respectively. In all panels, ‘‘Normal’’ 
refers to tumor mice, untreated with MA (a, d), ‘‘Tumor’’ indicates mice injected with EAC cells with no MA 
treatment (b, e). ‘‘Treated’’ refers to the mice bearing tumor treated orally with MA (c, f). In all the cases, a, b, c 
indicates images shown at 10X magnification, while d, e, f at 40X magnification 
 
 
 
Fig. 3. Evaluation of side effects of MA administration in Swiss albino mice on 20
th
 day 
Swiss albino mice, treated with MA (30 mg/kg b. wt, 9 doses) and untreated mice, were tested for various 
toxicological parameters after 20 days of treatment. A. Blood was collected and serum levels were checked for 
liver and kidney enzymes such as alkaline phosphatase (ALP), creatinine and urea. Variation in the counts of 
RBC and WBC were also compared following MA treatment. B. Body weight (g) was measured to assess the 
effect of MA following 20 days of oral administration. In all the cases, error bars indicate mean ± standard  
error mean 
 
mitochondrial pathways. In order to investigate 
whether the same holds true in tumor tissues, 
immunohistochemical analysis was performed 
using antibodies against protein markers of cell 
proliferation and apoptosis in histological 
sections of mouse tumor tissues following MA 
treatment (30 mg/ kg, 9 doses, 25
th
 day) (Fig. 4). 
We observed efficient Ki67 nuclear staining in 
untreated tumor sections (Fig. 4A (a, g)). while 
number of Ki67 positive cells were substantially 
less in MA treated tumors, although there was no 
significant difference in staining pattern between 
control and treated groups (Fig. 4A (b, h)). 
Besides we observed that the expression of 
proapoptotic protein, BID was significantly high 
following MA treatment compared to untreated 
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tumor tissues (Fig. 4A). This indicates the 
activation of intrinsic pathway of apoptosis in MA 
treated tumor tissues, which is consistent with 
our earlier studies that shows that MA induces 
intrinsic pathway of apoptosis [13,15,16]. Further, 
we also tested the expression of DNA repair 
protein, p53 binding protein, p53BP1. The 
expression of p53BP1 was significantly high in 
MA treated tissues compared to that in tumor 
tissues (Fig. 4B). Hence, our results suggest that 
MA treatment resulted in the abrogation of tumor 
cell proliferation by activating the apoptotic 
pathway in mice induced with carcinoma. 
 
4. DISCUSSION 
 
Compounds purified from medicinal plants have 
been considered as valuable sources for 
development of anticancer drugs. Differential 
effects of these natural products on tumor cells 
could be due to their difference in the efficacy to 
induce apoptotic pathways and this also might 
play a significant role in their chemopreventive 
potential. Among various plant derived 
molecules, limonoids are triterpenoids, which are 
biologically important and possess tumor 
preventive properties as shown by several in 
vitro and in vivo studies. Our previous studies, 
utilizing various cell line based assays, identified 
that MA possesses anticancer properties 
[13,15,16].  However, this is the first study to test 
the anticancer properties of MA in primary tumor 
tissues using an in vivo model system. 
 
Here, we have uncovered that MA has the 
potential to cause tumor regression in mice 
bearing breast adenocarcinoma. Further, this 
study, in conjunction with previous ex vivo 
studies show that MA activates intrinsic pathway 
of apoptosis to inhibit tumor growth [13,15,16].
 
 
 
Fig. 4. Immunohistochemical evaluation for cell proliferation, apoptosis and DNA damage 
markers following administration of MA 
Immunostaining studies in tumor and MA treated tissues on 25
th
 day. One representative animal from the treated 
and untreated tumor mice were used for the evaluation.  A. Antibody staining for Ki67, BID and 53BP1.  Although 
cell proliferation marker, Ki67 showed comparable staining in both control (a, g) and MA treated tissues (b, h), 
note that the number of surviving tumor cells were much less following MA treatment. Low BID expression in 
tumor tissue (c, i) versus high BID expression in MA treated tissue (d, j) is also noted. Low expression levels of 
53BP1 in tumor tissues (e, k) versus high expression levels in tumor bearing mice treated with MA (f, l) was also 
observed. Magnification of the images shown in upper panel is 10X, while lower panel is 40X.  B. The signals 
were quantified with the help of “ImageJ” software. Multiple images from control and treated groups were used for 
the quantification and the results were plotted and presented with error bars 
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Previous studies using tetranortriterpenoids have 
also shown their antiproliferative effects, 
particularly inhibition of carcinomas by inducing 
apoptosis [4,27-29]. Breast adenocarcinoma 
cells possess malignant features of cancer and 
are commonly used for inducing tumor in Swiss 
albino mice, for evaluating anticancer activity of 
small molecules in vivo.  
 
Several lines of evidence support that MA 
abrogated the tumor progression in EAC induced 
mice without adverse side effects. Our studies 
show more than 4-fold increase in lifespan 
following MA treatment compared to untreated 
tumour mice. Besides, there were no significant 
alterations in hepatic or renal functions and the 
whole blood cell counts following MA treatment. 
Histological evaluation of tumor and MA treated 
tumor tissues further indicates that effect of MA 
treatment was restricted to tumor cells and does 
not affect other organs. The present observation 
that oral administration of MA did not lead to any 
side effects was consistent with our previous 
findings of MA displaying no cytotoxicity in 
noncancerous cell lines [13,16]. We also tested 
the therapeutic potential of MA (30 mg/kg b. wt., 
9 doses) in the Dalton’s lymphoma mouse 
model. Our results showed no reduction of tumor 
in MA treated animals (data not shown). These 
results suggest that MA was effective against 
tumor induced by breast adenocarcinoma cells, 
while it was insensitive to tumors generated by 
Dalton lymphoma cells.  
 
Apoptosis is one of the important mechanisms, 
which determines the efficacy of anticancer 
drugs. Our previous findings showed that, upon 
treatment with MA, intrinsic pathway of apoptosis 
leading to cell death was activated in both 
leukemia and lymphoma cells. During apoptosis, 
proapoptotic proteins promote the release of 
mitochondrial Cytochrome C into cytoplasm, 
while antiapoptotic proteins block the 
Cytochrome C release by preserving the integrity 
of mitochondrial membrane. Previously, it has 
been shown that MA treatment resulted in 
increased BAD and decreased BCL2 
expressions leading to an altered ratio of 
antiapoptotic/proapoptotic proteins [13]. The 
increase in the BAD/BCL2 ratio resulted in 
disruption of mitochondrial membrane potential 
and Cytochrome C release, which in turn 
activated Caspase 9 and Caspase 3 culminating 
in cell death, indicating that MA displayed 
activation of the intrinsic pathway of apoptosis 
[13].  
In the present study, we measured expression of 
one of the proapoptotic proteins, (BID) in tumor 
tissues. An increase in BID expression in MA 
treated tumor tissues as compared to that in 
untreated tissues suggest that MA increased the 
levels of BID, causing its translocation from the 
cytosol into mitochondria. Thus, our findings in 
conjunction with previous studies suggested the 
activation of mitochondrial pathway of apoptosis 
following treatment with MA in tumor tissues. 
Similar activation of the intrinsic pathway has 
also reported in the case of other terpenoids [30-
32]. DNA damage is a critical event preceding 
cellular apoptosis. Accumulation of DNA double 
strand breaks leads to activation of apoptosis in 
cancer cells. The observed elevated expression 
of 53BP1 in tumor tissues was also consistent 
with this. Overall, DNA strand breakage following 
MA treatment in tumor cells supports the notion 
of activation of apoptosis in cancer cells and 
recapitulates DNA fragmentation induced by MA 
in cancer cell lines during apoptosis.  
 
5. CONCLUSIONS 
 
Taken together, our data suggests that MA 
abrogated tumor progression blocking cell 
proliferation by inducing intrinsic pathway of 
apoptosis in EAC induced mice as well increased 
life span of mice, with no adverse side effects to 
normal cells. Therefore, our current study in 
conjunction with previous reports reveals the 
potential of plant-derived MA as a potential 
cancer chemotherapeutic agent. 
 
CONSENT 
 
It is not applicable.  
 
COMPETING INTERESTS 
 
Authors have declared that no competing 
interests exist. 
  
REFERENCES 
 
1. Castrillo A, de Las Heras B, Hortelano S, 
Rodriguez B, Villar A, Bosca L. Inhibition of 
the nuclear factor kappa B (NF-kappa B) 
pathway by tetracyclic kaurene diterpenes 
in macrophages. Specific effects on NF-
kappa B-inducing kinase activity and on 
the coordinate activation of ERK and p38 
MAPK. The Journal of Biological 
Chemistry. 2001;276:15854-15860. 
 
 
 
 
Chiruvella et al.; BJMMR, 12(11): 1-10, 2016; Article no.BJMMR.21952 
 
 
 
9 
 
2. Bishayee A, S A, N B, M P. Triterpenoids 
as potential agents for the 
chemoprevention and therapy of breast 
cancer. Front Biosci. 2011;16:980-996. 
3. Kuo RY, Qian K, Morris-Natschke SL, Lee 
KH. Plant-derived triterpenoids and 
analogues as antitumor and anti-HIV 
agents. Natural Product Reports. 2009;26: 
1321-1344. 
4. Harish Kumar G, Vidya Priyadarsini R, 
Vinothini G, Vidjaya Letchoumy P, Nagini 
S. The neem limonoids azadirachtin and 
nimbolide inhibit cell proliferation and 
induce apoptosis in an animal model of 
oral oncogenesis. Investigational New 
Drugs. 2010;28:392-401. 
5. Lee JH, Koo TH, Hwang BY, Lee JJ. 
Kaurane diterpene, kamebakaurin, inhibits 
NF-kappa B by directly targeting the DNA-
binding activity of p50 and blocks the 
expression of antiapoptotic NF-kappa B 
target genes. The Journal of Biological 
Chemistry. 2002;277:18411-18420. 
6. Bickii J, Njifutie N, Foyere JA, Basco LK, 
Ringwald P. In vitro antimalarial activity of 
limonoids from Khaya grandifoliola C.D.C. 
(Meliaceae). J Ethnopharmacol. 2000;69: 
27-33. 
7. Thioune O, Pousset JL, Lo I. Anti-
inflammatory activity of the bark of Khaya 
senegalensis (A.Juss.). Preliminary 
research of structure and activity 
relationship. Dakar Med. 1994;44:12-15. 
8. Penido C, Costa KA, Costa MF, Pereira 
Jde F, Siani AC, Henriques MG. Inhibition 
of allergen-induced eosinophil recruitment 
by natural tetranortriterpenoids is mediated 
by the suppression of IL-5, CCL11/eotaxin 
and NFkappaB activation. International 
Immunopharmacology. 2006;6:109-121. 
9. Abdelgaleil SA, Hashinaga F, Nakatani M. 
Antifungal activity of limonoids from Khaya 
ivorensis. Pest Manag Sci. 2005;61:186-
190. 
10. Njar VC, Adesanwo JK, Raji Y. Methyl 
angolensate: the antiulcer agent of the 
stem bark of Entandrophragma angolense. 
Planta Med. 1995;61:91-92. 
11. Orisadipe A, Amos S, Adesomoju A, Binda 
L, Emeje M, Okogun J, Wambebe C, 
Gamaniel K. Spasmolytic activity of methyl 
angolensate: a triterpenoid isolated from 
Entandrophragma angolense. Biol Pharm 
Bull. 2001;24:364-367. 
12. Samir AM, Abdelgaleil Okamura H, 
Iwagawa T, Sato A, Miyahara I, Doe M, 
Nakatani M. Antifeedants from Khaya 
senegalensis. Tetrahedron. 2001;57:119-
126. 
13. Chiruvella KK, Kari V, Choudhary B, 
Nambiar M, Ghanta RG, Raghavan SC. 
Methyl angolensate, a natural 
tetranortriterpenoid induces intrinsic 
apoptotic pathway in leukemic cells. FEBS 
Lett. 2008;582:4066-4076. 
14. Chiruvella KK, Mohammed A, Dampuri G, 
Ghanta RG, Raghavan SC. Phytochemical 
and antimicrobial studies of Methyl 
Angolensate and Luteolin-7-O-glucoside 
isolated from callus cultures of Soymida 
febrifuga. Int J Biomed Sci. 2007;3:269-
278. 
15. Chiruvella KK, Panjamurthy K, Choudhary 
B, Joy O, Raghavan SC. Methyl 
angolensate from callus of Indian redwood 
induces cytotoxicity in human breast 
cancer cells. Int J Biomed Sci. 2010;6: 
182-194. 
16. Chiruvella KK, Raghavan SC. A natural 
compound, methyl angolensate, induces 
mitochondrial pathway of apoptosis in 
Daudi cells. Investigational New Drugs.  
2011;29:583-592. 
17. Sharma S, Panjamurthy K, Choudhary B, 
Srivastava M, Shahabuddin M, Giri R, 
Advirao GM, Raghavan SC. A novel DNA 
intercalator, 8-methoxy 
pyrimido[4',5':4,5]thieno (2,3-b)quinoline-
4(3H)-one induces apoptosis in cancer 
cells, inhibits the tumor progression and 
enhances lifespan in mice with tumor. 
Molecular Carcinogenesis. 2013;52:413-
425. 
18. Srivastava M, Nambiar M, Sharma S, Karki 
SS, Goldsmith G, Hegde M, Kumar S, 
Pandey M, Singh RK, Ray P, et al. An 
inhibitor of nonhomologous end-joining 
abrogates double-strand break repair and 
impedes cancer progression. Cell. 
2012;151:1474-1487. 
19. Noaman E, Badr El-Din NK, Bibars MA, 
Abou Mossallam AA, Ghoneum M. 
Antioxidant potential by arabinoxylan rice 
bran, MGN-3/biobran, represents a 
mechanism for its oncostatic effect against 
murine solid Ehrlich carcinoma. Cancer 
Letters. 2008;268:348-359. 
20. Srivastava M, Hegde M, Chiruvella KK, 
Koroth J, Bhattacharya S, Choudhary B, 
Raghavan SC. Sapodilla plum (Achras 
sapota) induces apoptosis in cancer cell 
 
 
 
 
Chiruvella et al.; BJMMR, 12(11): 1-10, 2016; Article no.BJMMR.21952 
 
 
 
10 
 
lines and inhibits tumor progression in 
mice. Scientific Reports. 2014;4:6147. 
21. Hegde M, Karki SS, Thomas E, Kumar S, 
Panjamurthy K, Ranganatha SR, 
Rangappa KS, Choudhary B, Raghavan 
SC. Novel levamisole derivative induces 
extrinsic pathway of apoptosis in cancer 
cells and inhibits tumor progression in 
mice. PloS One. 2012;7:e43632. 
22. Somasagara RR, Hegde M, Chiruvella KK, 
Musini A, Choudhary B, Raghavan SC. 
Extracts of strawberry fruits induce intrinsic 
pathway of apoptosis in breast cancer cells 
and inhibits tumor progression in mice. 
PloS One. 2012;7:e47021. 
23. Kumagai H, Mukaisho K, Sugihara H, 
Miwa K, Yamamoto G, Hattori T. 
Thioproline inhibits development of 
esophageal adenocarcinoma induced by 
gastroduodenal reflux in rats. 
Carcinogenesis. 2004;25:723-727. 
24. Srivastava M, Raghavan SC. DNA double-
strand break repair inhibitors as cancer 
therapeutics. Chemistry & Biology. 
2015;22:17-29. 
25. John F, George J, Srivastava M, Hassan 
PA, Aswal VK, Karki SS, Raghavan SC. 
Pluronic copolymer encapsulated SCR7 as 
a potential anticancer agent. Faraday 
Discussions; 2015. 
26. John F, George J, Vartak SV, Srivastava 
M, Hassan PA, Aswal VK, Karki SS, 
Raghavan SC. Enhanced efficacy of 
pluronic copolymer micelle encapsulated 
scr7 against cancer cell proliferation. 
Macromolecular Bioscience; 2014. 
27. Akudugu J, Gade G, Bohm L. Cytotoxicity 
of azadirachtin A in human glioblastoma 
cell lines. Life Sciences. 2001;68:1153-
1160. 
28. Akudugu JM, Bohm L. Micronuclei and 
apoptosis in glioma and neuroblastoma 
cell lines and role of other lesions in the 
reconstruction of cellular radiosensitivity. 
Radiation and Environmental Biophysics 
2001;40:295-300. 
29. Roy MK, Kobori M, Takenaka M, Nakahara 
K, Shinmoto H, Isobe S, Tsushida T. 
Antiproliferative effect on human cancer 
cell lines after treatment with nimbolide 
extracted from an edible part of the neem 
tree (Azadirachta indica). Phytotherapy 
Research: PTR. 2007;21:245-250. 
30. Ikai T, Akao Y, Nakagawa Y, Ohguchi K, 
Sakai Y, Nozawa Y. Magnolol-induced 
apoptosis is mediated via the intrinsic 
pathway with release of AIF from 
mitochondria in U937 cells. Biol Pharm 
Bull. 2006;29:2498-2501. 
31. Ohguchi K, Akao Y, Matsumoto K, Tanaka 
T, Ito T, Iinuma M, Nozawa Y. Vaticanol C-
induced cell death is associated with 
inhibition of pro-survival signaling in HL60 
human leukemia cell line. Biosci Biotechnol 
Biochem. 2005;69:353-356. 
32. Nakagawa Y, Iinuma M, Matsuura N, Yi K, 
Naoi M, Nakayama T, Nozawa Y, Akao Y. 
A potent apoptosis-inducing activity of a 
sesquiterpene lactone, arucanolide, in 
HL60 cells: a crucial role of apoptosis-
inducing factor. J Pharmacol Sci. 2005;97: 
242-252. 
_________________________________________________________________________________ 
© 2016 Chiruvella et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original work is properly cited. 
 
 
 Peer-review history: 
The peer review history for this paper can be accessed here: 
http://sciencedomain.org/review-history/12608 
